Sudarshan Pharma Industries Limited (SUDARSHAN) Fair Value & Analysis
Basic Materials · IN · Market cap ₹9.9B
Fair value as of: Jul 6, 2026
From 14 valuation models · updated today
Share price +14.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹19.23 – ₹39.95 · fair‑value band ₹11.90 – ₹22.09 · the ₹39.49 price screens above the ₹15.87 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sudarshan Pharma Industries Limited (SUDARSHAN) currently trades at ₹39.49, while our model-based Fair Value estimate is ₹15.87 — implying the stock looks roughly 59.8% overvalued today. We read business quality at 50/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sudarshan Pharma Industries Limited generated revenue of ₹7.0B at a net margin of 3.3%. Revenue grew 36.7% year over year. It earns a return on equity of 16.2%. Net debt stands at ₹2.8B. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹11.90 (bear case) to ₹22.09 (bull case); at ₹39.49, the current price sits above that range. The share trades about 2% below its 52-week high and 113% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -51% fair-value upside — at -60%, SUDARSHAN screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing. It also offers fine chemicals, solvents, agro chemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant specialties, paints and coatings, paper chemicals, personal and community hygiene products, pigments, polymers and additives, press room chemicals, sugar chemicals, textile chemicals, water treatment chemicals, rust preventives, metalworking fluids, PU additives, and other specialty chemicals. In addition, the company offers antibiotics, antifungal, anthelmintic medications, antihypertensive, anti-diabetic drugs, analgesics, neurotonics, antihistamines, and cough syrups, as well as manufactures and supplies chemicals and solvents. Further, it engages in the contract …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sudarshan Pharma Industries Limited reported revenue of ₹7.0B in FY2026 versus ₹3.6B in FY2022, a compound +18.5%/yr. Reported net income was ₹233M in FY2026, compounding +45.2%/yr from FY2022.
Is SUDARSHAN fairly valued? → Check now
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | €448.00 | €191.66 | -57% |
| Shin-Etsu Chemical Co SHECY | $22.77 | $13.22 | -42% |
| BASF SE BASFY | $13.97 | $6.79 | -51% |
| Ningxia Baofeng Energy Group 600989 | ¥22.46 | ¥37.07 | +65% |
| Dow Inc D1OW34 | R$43.92 | R$86.14 | +96% |
| Ganfeng Lithium Group 002460 | ¥65.65 | ¥18.75 | -71% |
| Hengli Petrochemical Co 600346 | ¥18.65 | ¥43.28 | +132% |
| Zangge Mining Company 000408 | ¥78.96 | ¥22.85 | -71% |
| Rongsheng Petrochemical Co 002493 | ¥11.43 | ¥2.90 | -75% |
| Zhejiang Juhua Co 600160 | ¥39.27 | ¥17.39 | -56% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Sudarshan Pharma Industries Limited (SUDARSHAN) undervalued?
What is the fair value of SUDARSHAN?
What is the quality score of SUDARSHAN?
What is the revenue of Sudarshan Pharma Industries Limited (SUDARSHAN)?
What is the net profit margin of SUDARSHAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.